ACHV vs PRLD
ACHV: A clinical-stage biotech developing cytisinicline for smoking cessation and nicotine dependence, preparing for commercialization after completing key clinical trials. PRLD: An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms.
Side-by-side fundamentals
| Metric | ACHV | PRLD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.31 | $3.92 | |
| Market cap as of 2026-07-23 | $646M | $313M | |
| Net margin as of 2026-07-23 | -94.7% | -278.5% | ACHV higher |
| Gross margin as of 2026-07-23 | -98.8% | n/a | |
| Operating margin as of 2026-07-23 | -106.5% | -310.7% | ACHV higher |
| ROE as of 2026-07-23 | -193.5% | -74.6% | PRLD higher |
| ROA as of 2026-07-23 | -111.9% | -39.3% | PRLD higher |
| Debt / equity as of 2026-07-23 | 1.40 | 0.00 | PRLD lower |
| Revenue growth (YoY) as of 2026-07-23 | -89.3% | +41.0% | PRLD higher |
| Beta as of 2026-07-23 | 2.28 | 0.94 | |
| 1-year return as of 2026-07-22 close | +144.4% | +379.8% | PRLD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.